Methods comprising apoptosis inhibitors for the generation of transgenic pigs

Stem Cell Clinic
Patient Application
FAQ
Contact
Locations
News
Videos
Research
Patents
3D Culture/Scaffold
Administration
Differentiation
Expansion
Extraction/Preservation
Mobilization
Type
USE
 


Stem Cell Related Patent Number US5846529

Title:Infusion of neutrophil precursors for treatment of neutropenia
Inventors:Smith, Stephen L.; Arlington Heights, IL, USA
Qiao, Xiaoying; Waukegan, IL, USA
Maciukas, SUSA
n M.; El Cerrito, CA, USA
Loudovaris, Maureen F.; Grayslake, IL, USA
Bender, James G.; Lindenhurst, IL, USA
Van Epps, Dennis E.; Cary, IL, USA
Summary:Described herein is a method of treating patients who exhibit a reduced population of neutrophils. The invention relates to the preparation of a serum-free and protein-free human cell suspension which is administered to a patient following a myeloablative cancer treatment such as high dose chemotherapy, after which a cell composition of at least 25% neutrophil precursors such as promyelocytes, myelocytes, and metamyelocytes is administered to the patient, after which a rapid in vivo differentiation of the neutrophil precursors replenishes the supply of mature neutrophils. Claims of the invention include a reduction in the neutropenic window between the time of myeloablative therapy and the time required for an infusion of stem cells to proliferate and differentiate into mature neutrophils. Therapeutic applications specifically directed to the treatment of neutropenia are included.
Abstract:The invention provides a method of treating a patient having a reduced population of neutrophils following a myeloablative cancer treatment such as high dose chemotherapy. Following myeloablative therapy, a cell composition of at least 25% neutrophil precursors, i.e. promyelocytes, myelocytes, and metamyelocytes, is administered to the patient. Thereafter, the neutrophil precursors differentiate rapidly in vivo to replenish the supply of mature neutrophils for fighting infection. The method is used to reduce the neutropenic window between the time of myeloablative therapy and the time required for infused stem cells to proliferate and differentiate into mature neutrophils.
US Patent Website:Click Here for Full Text of Patent
Title Number:US5846529
Application Number:US1995000376945
Date Filed:20/01/1995
Date Published:08/12/1998
Assignee:Nexell Therapeutics, Inc., Irvine, CA, USA


 
Copyright © 2007 The Institute for Cellular Medicine  8/15/2020